Recurrent Breast Carcinoma, Stage IV Breast Cancer
Conditions
Brief summary
This phase II trial studies how well erlotinib hydrochloride and bevacizumab work in treating patients with stage IV breast cancer. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving erlotinib hydrochloride and bevacizumab may be an effective treatment for breast cancer.
Detailed description
PRIMARY OBJECTIVES: I. To determine the efficacy of bevacizumab in combination with OSI-774 (erlotinib hydrochloride) in patients with previously treated metastatic breast cancer, as measured by objective response rate. SECONDARY OBJECTIVES: I. To determine the toxicity of bevacizumab in combination with OSI-774 in patients with previously treated metastatic breast cancer. II. To evaluate the efficacy of bevacizumab in combination with OSI-774 in patients with previously treated metastatic breast cancer, as measured by time to disease progression, duration of response and the proportion of patients with stabilization of disease \>= 6 months. III. To determine the molecular profile of the patient's primary breast tumor, and to explore the relationship between these molecular characteristics and the response to treatment. IV. To explore changes in biological markers in pre- and post-treatment tumor tissue in a subset of patients with accessible sites of disease. V. To explore a pre- and post-treatment analysis of circulating endothelial cells and the relationship of this analysis to serum markers of angiogenesis as well as response to treatment. VI. To obtain serial measurements of circulating epithelial cells and explore the relationship of these cells with circulating endothelial cells, markers of angiogenesis, and epidermal growth factor receptor (EGFR) expression. OUTLINE: Patients receive erlotinib hydrochloride orally (PO) once daily (QD) on days 1-21 and bevacizumab intravenously (IV) over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up periodically.
Interventions
BIOLOGICALBevacizumab
Given IV
DRUGErlotinib Hydrochloride
Given PO
OTHERLaboratory Biomarker Analysis
Correlative studies
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have histologically or cytologically confirmed carcinoma of the breast with metastatic (stage IV) disease that is currently stable or progressing after therapy * Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \>= 20 mm with conventional techniques or as \>= 10 mm with spiral computed tomography (CT) scan * Patients must have either stable disease or disease progression on or after therapy with one or two conventional chemotherapy regimens for the treatment of metastatic (stage IV) breast cancer * Prior treatment with high-dose chemotherapy and autologous stem cell/bone marrow transplantation is allowed, and is considered one prior regimen when administered for metastatic disease * There is no restriction for the number of prior hormonal therapies or immunotherapies * If human epidermal growth factor receptor 2 (Her2)/neu-positive (defined as 3+ by immunohistochemistry \[IHC\] or positive by fluorescence in situ hybridization \[FISH\]), prior therapy with trastuzumab required * Any number of prior regimens of chemotherapy and/or hormonal therapy are allowed in the adjuvant setting, and do not count towards prior therapy when determining eligibility for this trial * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 (Karnofsky \>= 60%) * Life expectancy of greater than 3 months * Leukocytes \>= 3,000/ul * Absolute neutrophil count \>= 1,000/ul * Platelets \>= 75,000/ul * Total bilirubin within normal institutional limits * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\[) =\< 2.5 X institutional upper limit of normal * Creatinine within normal institutional limits OR creatinine clearance \>= 60 mL/min for patients with creatinine levels outside institutional normal using the Cockcroft-Gault formula * Women of childbearing potential must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately * Patients must have breast cancer tissue available as either paraffin blocks or unstained slides for planned correlative science sub study * Ability to understand and the willingness to sign a written informed consent document
Exclusion criteria
* Patients who have had chemotherapy, radiotherapy immunotherapy or investigational therapy within 3 weeks prior to starting treatment (6 weeks for nitrosoureas or mitomycin C), or hormonal therapy within 2 weeks prior to starting treatment * Patients may not be receiving any other investigational agents * History or evidence upon physical examination of central nervous system (CNS) disease (e.g., primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of stroke); all subjects must have a baseline CT or magnetic resonance imaging (MRI) of the head * History of allergic reactions attributed to compounds of similar chemical or biologic composition to OSI-774 or bevacizumab * Prior treatment with kinase insert domain receptor (KDR) inhibitors (e.g. vascular endothelial growth factor \[VEGF\] Trap, Su5416, Su6668, ZD6474, PTK757, IMC-1CII) * Prior treatment with EGFR targeting therapies (e.g. ZD1839 or C225) * Major surgery, open biopsy or significant traumatic injury occurring within 28 days prior to treatment; this does not apply to indwelling catheters, which require an interval of at least 24 hours between placement of the catheter and treatment with bevacizumab * Current or recent (within 10 days prior to treatment) use of full-dose oral or parenteral anticoagulants or thrombolytic agents (except as required to maintain patency of preexisting, permanent indwelling IV catheters; for subjects receiving warfarin, international normalized ratio \[INR\] should be \< 1.5) * Chronic daily treatment with aspirin (\> 325 mg/day) or nonsteroidal anti-inflammatory medications known to inhibit the platelet function (e.g. cyclooxygenase \[COX\]-1 inhibitors) * Presence of bleeding diathesis or coagulopathy * Cumulative anthracycline and anthracenedione exposure as follows: doxorubicin \> 450 mg/m\^2; epirubicin \> 700 mg/m\^2; liposomal doxorubicin \> 550 mg/m\^2; mitoxantrone \> 140 mg/m\^2 * Proteinuria at baseline; subjects unexpectedly discovered to have \>= 1+ proteinuria should undergo a 24-hour urine collection, which must be an adequate collection and must demonstrate =\< 500 mg protein/ 24 hours to allow participation in the study * Cardiac ejection fraction (multigated acquisition scan \[MUGA\] or echocardiogram) less than the local institution lower limit of normal * Abnormalities of the cornea based on history (e.g., dry eye syndrome, Sjögren's syndrome), congenital abnormality (e.g., Fuch's dystrophy), abnormal slit-lamp examination using a vital dye (e.g., fluorescein, Bengal-Rose), and/or an abnormal corneal sensitivity test (Schirmer test or similar tear production test) * Serious, non-healing wound, ulcer, or bone fracture * Clinically significant cardiovascular disease (e.g., uncontrolled hypertension, myocardial infarction, unstable angina), New York Heart Association (NYHA) grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, or grade II or greater peripheral vascular disease within 1 year prior to day 0 * Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, or prior surgical procedures affecting absorption * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with OSI-774 * Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study * Patients with recent (within 6 months) arterial thrombotic events, including transient ischemic attack (TIA), cerebrovascular accident (CVA), unstable angina, myocardial infarction (MI), or clinically significant peripheral artery disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Level of EGFR Expression | Up to 12 years | Estimated at the end of the trial Immunoreactivity will be evaluated qualitatively with regard to intensity as follows: Measured on a scale, ranging from 0-3+ 0=negative (no immunoreactivity) 1+ - 3+ = positive: * faint immunoreactivity (weak staining) * intense immunoreactivity (strong staining) Immunohistochemical studies will be performed on the tumor specimen to correlate the anti-tumor efficacy of OSI-774 and bevacizumab with pre-treatment molecular characteristics. |
| Response Rate, Defined as Complete Response (CR) + Partial Response (PR), Using the Response Evaluation Criteria in Solid Tumors | Up to 12 years | Estimated at the end of the trial. Complete Response (CR):Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD 55 Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Response | From the time measurement criteria are met for CR and PR until the first date that recurrent or progressive disease is objectively documented, assessed up to 12 years | The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started).Evaluation of Target Lesions Complete Response (CR):Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD |
| Time to Progression | From the start of treatment until the first date that recurrent or progressive disease is objectively documented, assessed up to 12 years | Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions |
| Number of Patients Evaluated for Toxicity | up to 12 years | graded according to the National Cancer Institute Common Toxicity Criteria version 4.0 |
| Participants With Duration of Stable Disease Greater Than or Equal to 6 Months | From the start of treatment until the first date that recurrent or progressive disease is objectively documented, assessed up to 12 years | Duration of stable disease greater than or equal to 6 months |
Other
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Cells Staining Positive for Phosphorylated-v-akt Murine Thymoma Viral Oncogene Homolog 1 (Akt) | Up to 12 years | Associations between markers and tumor response will be assessed by logistic regression analysis. For those markers that are statistically significant, a cut-point analysis will be performed by the maximum chi-square with p-value adjustment method to determine positive values. |
| Percentage of Cells Staining Positive for Tumor Protein p53 (p53) | Up to 12 years | Associations between markers and tumor response will be assessed by logistic regression analysis. For those markers that are statistically significant, a cut-point analysis will be performed by the maximum chi-square with p-value adjustment method to determine positive values. |
| HER2 Status | Up to 12 years | Associations between response and HER2 will be assessed by Fisher's exact test. |
| Percentage of Cells Staining Positive for VEGF Receptor (VEGFR)-1 | Up to 12 years | Associations between markers and tumor response will be assessed by logistic regression analysis. For those markers that are statistically significant, a cut-point analysis will be performed by the maximum chi-square with p-value adjustment method to determine positive values. |
| Percentage of Cells Staining Positive for VEGFR-2 | Up to 12 years | Associations between markers and tumor response will be assessed by logistic regression analysis. For those markers that are statistically significant, a cut-point analysis will be performed by the maximum chi-square with p-value adjustment method to determine positive values. |
| Percentage of Cells Staining Positive for VEGF | Up to 12 years | Associations between markers and tumor response will be assessed by logistic regression analysis. For those markers that are statistically significant, a cut-point analysis will be performed by the maximum chi-square with p-value adjustment method to determine positive values. |
| Percentage of Cells Staining Positive for EGFR | Up to 12 years | Associations between markers and tumor response will be assessed by logistic regression analysis. For those markers that are statistically significant, a cut-point analysis will be performed by the maximum chi-square with p-value adjustment method to determine positive values. |
| Percentage of Cells Staining Positive for Human Epidermal Growth Factor Receptor 3 (HER3) | Up to 12 years | Associations between markers and tumor response will be assessed by logistic regression analysis. For those markers that are statistically significant, a cut-point analysis will be performed by the maximum chi-square with p-value adjustment method to determine positive values. |
| Percentage of Cells Staining Positive for Marker of Proliferation Ki-67 (Ki-67) | Up to 12 years | Associations between markers and tumor response will be assessed by logistic regression analysis. For those markers that are statistically significant, a cut-point analysis will be performed by the maximum chi-square with p-value adjustment method to determine positive values. |
| Percentage of Cells Staining Positive for p27 | Up to 12 years | Associations between markers and tumor response will be assessed by logistic regression analysis. For those markers that are statistically significant, a cut-point analysis will be performed by the maximum chi-square with p-value adjustment method to determine positive values. |
| Percentage of Cells Staining Positive for Phosphorylated-mitogen-activated Protein Kinase (MAP) Kinase | Up to 12 years | Associations between markers and tumor response will be assessed by logistic regression analysis. For those markers that are statistically significant, a cut-point analysis will be performed by the maximum chi-square with p-value adjustment method to determine positive values. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Treatment (Erlotinib Hydrochloride, Bevacizumab) Patients receive erlotinib hydrochloride PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. | 38 |
| Total | 38 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Not Treated | 1 |
Baseline characteristics
| Characteristic | Treatment (Erlotinib Hydrochloride, Bevacizumab) |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 4 Participants |
| Age, Categorical Between 18 and 65 years | 34 Participants |
| Region of Enrollment United States | 38 participants |
| Sex: Female, Male Female | 38 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 32 / 38 |
| serious Total, serious adverse events | 6 / 38 |
Outcome results
Primary
Level of EGFR Expression
Estimated at the end of the trial Immunoreactivity will be evaluated qualitatively with regard to intensity as follows: Measured on a scale, ranging from 0-3+ 0=negative (no immunoreactivity) 1+ - 3+ = positive: * faint immunoreactivity (weak staining) * intense immunoreactivity (strong staining) Immunohistochemical studies will be performed on the tumor specimen to correlate the anti-tumor efficacy of OSI-774 and bevacizumab with pre-treatment molecular characteristics.
Time frame: Up to 12 years
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment (Erlotinib Hydrochloride, Bevacizumab) | Level of EGFR Expression | EGFR 0 | 24 participants |
| Treatment (Erlotinib Hydrochloride, Bevacizumab) | Level of EGFR Expression | EGFR 1+ | 8 participants |
| Treatment (Erlotinib Hydrochloride, Bevacizumab) | Level of EGFR Expression | EGFR 2+ | 4 participants |
| Treatment (Erlotinib Hydrochloride, Bevacizumab) | Level of EGFR Expression | EGFR 3+ | 0 participants |
| Treatment (Erlotinib Hydrochloride, Bevacizumab) | Level of EGFR Expression | Insufficient tumor tissue | 2 participants |
Primary
Response Rate, Defined as Complete Response (CR) + Partial Response (PR), Using the Response Evaluation Criteria in Solid Tumors
Estimated at the end of the trial. Complete Response (CR):Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD 55 Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started
Time frame: Up to 12 years
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment (Erlotinib Hydrochloride, Bevacizumab) | Response Rate, Defined as Complete Response (CR) + Partial Response (PR), Using the Response Evaluation Criteria in Solid Tumors | Complete Response | 0 participants |
| Treatment (Erlotinib Hydrochloride, Bevacizumab) | Response Rate, Defined as Complete Response (CR) + Partial Response (PR), Using the Response Evaluation Criteria in Solid Tumors | Partial Response | 1 participants |
| Treatment (Erlotinib Hydrochloride, Bevacizumab) | Response Rate, Defined as Complete Response (CR) + Partial Response (PR), Using the Response Evaluation Criteria in Solid Tumors | Stable Disease | 17 participants |
| Treatment (Erlotinib Hydrochloride, Bevacizumab) | Response Rate, Defined as Complete Response (CR) + Partial Response (PR), Using the Response Evaluation Criteria in Solid Tumors | Progression of Disease | 19 participants |
Secondary
Duration of Response
The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started).Evaluation of Target Lesions Complete Response (CR):Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD
Time frame: From the time measurement criteria are met for CR and PR until the first date that recurrent or progressive disease is objectively documented, assessed up to 12 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Erlotinib Hydrochloride, Bevacizumab) | Duration of Response | 52 months |
Secondary
Number of Patients Evaluated for Toxicity
graded according to the National Cancer Institute Common Toxicity Criteria version 4.0
Time frame: up to 12 years
Population: Please see adverse events section.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Erlotinib Hydrochloride, Bevacizumab) | Number of Patients Evaluated for Toxicity | 38 Participants |
Secondary
Participants With Duration of Stable Disease Greater Than or Equal to 6 Months
Duration of stable disease greater than or equal to 6 months
Time frame: From the start of treatment until the first date that recurrent or progressive disease is objectively documented, assessed up to 12 years
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Erlotinib Hydrochloride, Bevacizumab) | Participants With Duration of Stable Disease Greater Than or Equal to 6 Months | 0 Participants |
Secondary
Time to Progression
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
Time frame: From the start of treatment until the first date that recurrent or progressive disease is objectively documented, assessed up to 12 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Erlotinib Hydrochloride, Bevacizumab) | Time to Progression | 11 weeks |
Other Pre-specified
HER2 Status
Associations between response and HER2 will be assessed by Fisher's exact test.
Time frame: Up to 12 years
Other Pre-specified
Percentage of Cells Staining Positive for EGFR
Associations between markers and tumor response will be assessed by logistic regression analysis. For those markers that are statistically significant, a cut-point analysis will be performed by the maximum chi-square with p-value adjustment method to determine positive values.
Time frame: Up to 12 years
Other Pre-specified
Percentage of Cells Staining Positive for Human Epidermal Growth Factor Receptor 3 (HER3)
Associations between markers and tumor response will be assessed by logistic regression analysis. For those markers that are statistically significant, a cut-point analysis will be performed by the maximum chi-square with p-value adjustment method to determine positive values.
Time frame: Up to 12 years
Other Pre-specified
Percentage of Cells Staining Positive for Marker of Proliferation Ki-67 (Ki-67)
Associations between markers and tumor response will be assessed by logistic regression analysis. For those markers that are statistically significant, a cut-point analysis will be performed by the maximum chi-square with p-value adjustment method to determine positive values.
Time frame: Up to 12 years
Other Pre-specified
Percentage of Cells Staining Positive for p27
Associations between markers and tumor response will be assessed by logistic regression analysis. For those markers that are statistically significant, a cut-point analysis will be performed by the maximum chi-square with p-value adjustment method to determine positive values.
Time frame: Up to 12 years
Other Pre-specified
Percentage of Cells Staining Positive for Phosphorylated-mitogen-activated Protein Kinase (MAP) Kinase
Associations between markers and tumor response will be assessed by logistic regression analysis. For those markers that are statistically significant, a cut-point analysis will be performed by the maximum chi-square with p-value adjustment method to determine positive values.
Time frame: Up to 12 years
Other Pre-specified
Percentage of Cells Staining Positive for Phosphorylated-v-akt Murine Thymoma Viral Oncogene Homolog 1 (Akt)
Associations between markers and tumor response will be assessed by logistic regression analysis. For those markers that are statistically significant, a cut-point analysis will be performed by the maximum chi-square with p-value adjustment method to determine positive values.
Time frame: Up to 12 years
Other Pre-specified
Percentage of Cells Staining Positive for Tumor Protein p53 (p53)
Associations between markers and tumor response will be assessed by logistic regression analysis. For those markers that are statistically significant, a cut-point analysis will be performed by the maximum chi-square with p-value adjustment method to determine positive values.
Time frame: Up to 12 years
Other Pre-specified
Percentage of Cells Staining Positive for VEGF
Associations between markers and tumor response will be assessed by logistic regression analysis. For those markers that are statistically significant, a cut-point analysis will be performed by the maximum chi-square with p-value adjustment method to determine positive values.
Time frame: Up to 12 years
Other Pre-specified
Percentage of Cells Staining Positive for VEGFR-2
Associations between markers and tumor response will be assessed by logistic regression analysis. For those markers that are statistically significant, a cut-point analysis will be performed by the maximum chi-square with p-value adjustment method to determine positive values.
Time frame: Up to 12 years
Other Pre-specified
Percentage of Cells Staining Positive for VEGF Receptor (VEGFR)-1
Associations between markers and tumor response will be assessed by logistic regression analysis. For those markers that are statistically significant, a cut-point analysis will be performed by the maximum chi-square with p-value adjustment method to determine positive values.
Time frame: Up to 12 years